Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$25.92 -2.8%	$22.84	$12.21 ▼ $41.31	$783.87M	-0.27	649,273 shs	334,038 shs
BSTC BioSpecifics Technologies	$88.53	$88.47	$42.00 ▼ $89.15	$650.25M	0.24	61,105 shs	N/A
BYSI BeyondSpring	$2.18 -0.9%	$2.19	$0.98 ▼ $3.44	$88.70M	0.17	31,864 shs	12,767 shs
MRSN Mersana Therapeutics	$0.35 -2.9%	$0.35	$0.26 ▼ $2.83	$45.28M	0.79	2.78 million shs	1.49 million shs
PGNX Progenics Pharmaceuticals	$4.10	$4.10	$1.89 ▼ $6.37	$355.05M	1.89	1.16 million shs	34.93 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-0.67%	+2.26%	+12.01%	+29.83%	-22.58%
BSTC BioSpecifics Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
BYSI BeyondSpring	-0.45%	-2.22%	-35.29%	+67.94%	-4.18%
MRSN Mersana Therapeutics	+7.07%	-4.39%	+2.80%	+2.42%	-83.18%
PGNX Progenics Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.7273 of 5 stars	3.4	0.0	0.0	0.0	1.6	2.5	0.6
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	4.1921 of 5 stars	3.5	3.0	0.0	4.1	2.7	2.5	0.0
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	63.48% Upside
BSTC BioSpecifics Technologies	0.00	N/A	N/A	N/A
BYSI BeyondSpring	0.00	N/A	N/A	N/A
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,373.92% Upside
PGNX Progenics Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BSTC, MRSN, ANAB, BYSI, and PGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	8.34	N/A	N/A	$2.33 per share	11.12
BSTC BioSpecifics Technologies	$38.19M	17.03	$3.38 per share	26.18	$18.42 per share	4.81
BYSI BeyondSpring	$1.75M	50.23	N/A	N/A	($0.37) per share	-5.89
MRSN Mersana Therapeutics	$40.50M	1.09	N/A	N/A	($0.08) per share	-4.41
PGNX Progenics Pharmaceuticals	$34.99M	10.15	N/A	N/A	$0.54 per share	7.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	0.00	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
BSTC BioSpecifics Technologies	$24.47M	$3.33	37.51	17.60	N/A	47.43%	14.81%	14.46%	N/A
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	-$69.19M	-$0.59	0.00	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
PGNX Progenics Pharmaceuticals	-$68.55M	-$0.80	N/A	N/A	N/A	-180.28%	-129.46%	-53.23%	N/A

Latest BSTC, MRSN, ANAB, BYSI, and PGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/4/2025	Q2 2025	ANAB AnaptysBio	-$1.47	N/A	N/A	N/A	$11.55 million	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
BSTC BioSpecifics Technologies	N/A	66.24	66.24
BYSI BeyondSpring	N/A	2.49	2.49
MRSN Mersana Therapeutics	N/A	1.83	1.83
PGNX Progenics Pharmaceuticals	0.99	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
BSTC BioSpecifics Technologies	60.34%
BYSI BeyondSpring	40.29%
MRSN Mersana Therapeutics	93.92%
PGNX Progenics Pharmaceuticals	70.96%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
BSTC BioSpecifics Technologies	15.70%
BYSI BeyondSpring	29.31%
MRSN Mersana Therapeutics	13.00%
PGNX Progenics Pharmaceuticals	4.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
BSTC BioSpecifics Technologies	7	7.35 million	N/A	Not Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
PGNX Progenics Pharmaceuticals	79	86.60 million	N/A	Optionable

BSTC, MRSN, ANAB, BYSI, and PGNX Headlines

Recent News About These Companies

Antibody–drug conjugates for cancer: poised to deliver?

October 28, 2024 | nature.comN

BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals

August 19, 2024 | br.advfn.com

PGNX_old Historical Data

October 28, 2023 | investing.com

Investing in Pharmaceutical Stocks

March 3, 2023 | fool.com

Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Quotes and News Summary

February 24, 2023 | benzinga.com

Opioid Induced Constipation (OIC) Drug Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028

February 13, 2023 | marketwatch.com

Insights on the Flexible Manufacturing Systems for Pharmaceutical Industry Global Market to 2031 - by Product Type, Technology, End-user and Region

February 11, 2023 | finance.yahoo.com

I've Got an Options Bandage for a Sick Economy

June 19, 2022 | realmoney.thestreet.com

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

January 21, 2022 | thestreet.com

What Falling Estimates & Price Mean for Progenics (PGNX)

October 26, 2021 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BSTC, MRSN, ANAB, BYSI, and PGNX Company Descriptions

AnaptysBio NASDAQ:ANAB

$25.92 -0.76 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$25.93 +0.01 (+0.04%)

As of 04:33 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

BioSpecifics Technologies NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

BeyondSpring NASDAQ:BYSI

$2.18 -0.02 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 +0.00 (+0.23%)

As of 04:23 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Mersana Therapeutics NASDAQ:MRSN

$0.35 -0.01 (-2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 0.00 (-0.23%)

As of 07:49 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time